Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Sales reflect continued strong growth in oncology and vaccines
Submission based on results from pivotal phase III trial showing all primary endpoints met
Subscribe To Our Newsletter & Stay Updated